

Press release
13 November, 2025

Curasight to present at Dansk Aktionærforening InvestorDagen

Copenhagen, Denmark, 13 November 2025 - Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff will present the company's latest progress and strategy at Dansk Aktionærforening InvestorDagen in Copenhagen on Monday, 17th November 2025.

Management will provide an overall update on the company's pipeline based on Curasight's proprietary uPAR theranostics platform which is aimed at improving diagnosis and treatment of certain types of cancers including prostate and brain cancer. The presentation will also highlight key near-term milestones for both this and next year.

The Dansk Aktionærforening InvestorDagen presentation takes place 10:30 - 10:55 (CET), Monday 17 November 2025.

A recording of the webcast will be available on Curasight's website after the event.

Further information about Dansk Aktionærforening InvestorDagen [click here](#)

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.